2/ FH, particularly HoFH is highly associated with atherosclerosis and is considered a substantial risk.
Cases of HoFH are extremely rare, but are considered a cornerstone of the lipid hypothesis as many with LDL-C levels (comparable to Nick's) demonstrate CVD as children...
3/ Brown and Goldstein have seminal work on this topic.
(Warning: this includes many graphic images of xanthomas, which are more common with high LDL FH)
4/ "The early atherosclerosis in homozygous FH children who do not have any other risk factors (e.g., smoking, hypertension, diabetes, type A personality) provides formal genetic proof that elevated LDL alone can produce atherosclerosis in humans."
5/ While it's true that I'm "cautiously optimistic" with regard to higher LDL-C / ApoB in the context of metabolic fat adaptation (see below), I'm by no means certain.
I'm not just waxing philosophic. I have LDL-C at 1/2 of Nick's on #keto at ~250 mg/dL
6/ As always, I point to the set of clues on metabolic fat adaptation that (I hypothesize, per the model) typically results in high HDL and low TG that we see in this phenotype, the so called "Lipid Triad" (Triad) of ⬆️LDL+⬆️HDL+⬇️TG.
But I won't go into detail on that here...
7/ Just note we are not outliers. At the CC site, CC and LMHR Facebook groups, and recent surveys like (
) I can say with confidence there are *at least* tens of thousands with LDL ≥ 200, and *at least* over a hundred with LDL ≥ 500 (w/ ⬆️HDL+⬇️TG).
8/ So let me restate this for extra emphasis: We don't know if this population is at considerable risk for atherosclerosis.
When I say I'm "cautiously optimistic", don't read as "completely certain"- or I wouldn't be working so hard to help gather key data, such as this study
9/ For better or for worse, the LMHR phenotypes afford a uniquely distinctive population for testing the exposure of interest (LDL-C/ApoB) in the absence of other major CVD risk factors to better confirm it's independent atherogenicity.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
2/ If you've followed me a while, you know I believe it isn't the actual ingestion of cholesterol on #LowCarb that has a big impact on serum levels -- it's predominantly the trafficking of fat. (See CholesterolCode.com/model)
But this is actually a very testable distinction...
3/ All we need is an experiment where I consume a lot of (1) low fat food that still (2) has ample amounts of cholesterol.
Thus, the "processed meat" side of the experiment is key if it has a decent amount of cholesterol -- and it does.
If a drug did many of the same things with one's lipid profile as a #LowCarb diet, particularly decreasing triglycerides while increasing #LDL#Cholesterol:
1) Would it reduce ASCVD risk? 2) And if so, would it be more acceptable than #LowCarb?
2/ If you haven't heard, SGLT2 Inhibitors have recently emerged and have been gaining a lot of popularity. Data thus far shows they typically:
3/ Naturally, that has the attention for those of us interested in how triglyceride trafficking and turnover could be relevant to #LDL increasing for what may turn out to be non-pathogenic reasons (kinda my focus ;) )
2/ Per @Lpa_Doc's (2) and (3) in the thread, when we have "normal" TG levels (guidelines would say < 150, I prefer < 100) then most cholesterol in ApoB-containing lipoproteins (ApoB-Lp) are in LDL and there's little VLDL-cholesterol...
3/ But where TG is high, there's more utility in looking at ApoB given it lumps remnants (VLDL/IDL) with LDL.
-- But IMO, that's also the problem. We want to disentangle where remnant association is much more relevant than LDL association...
1/ I’ll be interviewing @KetoCarnivore soon. In preparation, I watched this talk of hers from 2019 that I found very interesting...
2/ She provides some counter opinion analysis regarding both simplified metrics of “nutrient density” and the protein leverage hypothesis (ie @tednaiman). Or more specifically, the challenge in these approaches having potential bias that isn’t easily apparent...
3/ To be sure, I don’t have a very strong opinion myself in this area as I tend to focus more on lipid trafficking (and generally try to avoid the nutrition debates overall).
Moreover, I’m still plotting to do @tednaiman’s P:E diet as an experiment soon along w/bloodwork...
2- There may be online services that you can order it with, but to be honest, I haven't checked which do yet
3- We offer it and other Boston Heart tests through OwnYourLabs, but full disclosure, this program is a beta right now. You can sign up here: ownyourlabs.com/boston-heart-b…
3/ If you do get the test, please consider sharing back the data to us at CholesterolCode.com. I'm especially interested to see if this data further confirms my hypothesis that the majority of hyper-responders will generally have relatively low OxPL in spite of very high ApoB